Anavex Life Sciences Stock Jumps As Blarcamesine Shows Convincing Biomarker-Correlating Efficacy Data In Parkinson's Disease Dementia Patients

Loading...
Loading...
  • Anavex Life Sciences Corp AVXL has reported that SIGMAR1 mRNA expression correlates positively with responses in efficacy endpoints in the Phase 2 trial of ANAVEX 2-73 (blarcamesine) in patients with Parkinson's disease dementia.
  • ANAVEX 2-73 activates the sigma-1 receptor (SIGMAR1), restoring neural cell homeostasis and promoting neuroplasticity.
  • Blarcamesine high dose demonstrated statistically significant improvements compared to placebo for MDS-UPDRS Total score. 
  • MDS-UPDRS Total score improved by -10.98 points in the ANAVEX2-73 high dose group and worsened by 3.53 points in the placebo group, an adjusted mean difference of -14.51. This corresponds to a relative improvement of 18.9 % over 14 weeks.
  • Previously reported cognitive outcome measures from this study observed statistically significant improvement of CDR system Episodic Memory of +42.22 between ANAVEX 2-73 high dose and placebo dose-dependent.
  • 7 CDR system Episodic Memory is highly correlated (70%) with the ADAS-Cog score. 
  • The difference between the ANAVEX2-73 group and the placebo group in the change from baseline at 14 weeks was a 4.0-point improvement.
  • Last week, the company reported a similar biomarker correlating efficacy data in Rett Syndrome patients.
  • HC Wainwright & Co. analyst Raghuram Selvaraju maintained Anavex Life Sciences with a Buy rating and raised the price target from $25 to $39.
  • Price Action: AVXL shares are up 28.5% at $31.8 during the premarket session on the last check Monday.
Loading...
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsdementiaParkinson’s Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...